A promising drug could be the first of an entirely new class of treatmentsPhotograph: Cristina SpanòScientists are not usually an excitable bunch. So when many thousands of them recently gave a spontaneous standing ovation (with cheering) in the middle of a lecture, it meant something special happened. At a conference in Chicago at the end of May oncologists went wild over the results of a drug called daraxonrasib, which treats pancreatic cancer. The drug almost doubled median survival times fro...